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Background and objectives 
The Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial was a large pilot 
study for a cluster randomised trial of AKI Outreach.  
Design, Setting, Participants, and Measurements 
An observational Control (Before) phase was conducted in two teaching hospitals (9 miles 
apart) and their respective catchment areas. In the Intervention (After) phase, a working hours AKI 
outreach service operated for the intervention hospital/area for 20 weeks, with the other site acting 
as a control. All AKI alerts in both hospital and community patients were screened for inclusion. 
Major exclusion criteria were patients who were end of life, or unlikely to benefit from Outreach, or 
lacking mental capacity, or already referred to the Renal team. The intervention arm included a 
model of escalation of renal care to AKI patients, depending on AKI stage. The 30-day primary 
outcome was a combination of death, or deterioration, as shown by any need for dialysis or 
progression in AKI stage. 1762 adult patients were recruited; 744 at the Intervention site during the 
After phase. 
Results 
A median of 3.0 non-medication recommendations and 0.5 medication related recommendations 
per patient were made by the Outreach team, a median of 15.7 hours after the AKI alert. Relatively 
low rates of the primary outcomes of death within 30 days (11-15%), or requirement for dialysis 
(0.4 – 3.7%) were seen across all four groups. In an exploratory analysis, at the Intervention 
hospital during the After phase the was an odds ratio for the combined primary outcome of 0.73 
(95% CI 0.42, 1.26, p = 0.26). 
Conclusions 
An AKI outreach service can provide standardised specialist care to those with AKI across a 
healthcare economy. Trials assessing AKI outreach may benefit from focusing on those 




Acute Kidney Injury (AKI) is known to occur in up to 20% of emergency admissions to hospital [1, 
2] when the KDIGO or AKIN definitions are used.[3] Increasing AKI severity is closely associated 
with worsening mortality, length of stay and costs.[1, 4, 5] AKI has been recognised as leading to 
CKD and ESRD, with the risk rising with increasing severity of AKI.[6, 7]  
Care of patients who develop AKI has long been recognised as being suboptimal,[8] a finding 
present even in recent literature.[9, 10] A seminal National inquiry into AKI care in the UK showed 
significant flaws in AKI care, and suggested that 14% of all cases AKI were avoidable, with 31% of 
post admission AKI being avoidable.[9] This led to the introduction of a National alert system for 
AKI in England and Wales.[11] 
There is observational data suggesting that delayed referral and nephrology consultation is 
associated with poorer outcomes in critical care[12-14] and in general hospital admissions.[15] The 
medical emergency team (or critical care outreach) was developed to detect and treat deterioration 
in hospitalised patients at an earlier stage, based on vital signs monitoring.[16] However, in spite of 
the potential benefits, a major trial of a rapid response system failed to show improved 
outcomes.[17]  
With the advent of sophisticated laboratory information systems and more frequent creatinine 
testing it has been possible to develop alerts that warn clinicians of the development of possible 
AKI.[18-21] However, the implementation of a “standalone” alert system for AKI did not improve 
outcomes.[22] We hypothesised that “Outreach”, combining the use of alerts together with early 
Nephrology consultation, could improve outcomes in AKI. We[23] and others[24] have tested the 






Study design and participants 
The trial protocol has been published.[25] In brief, we ran a study of a complex multifactorial 
intervention,[26] as a pilot for a cluster randomised trial. Using a Before and After study design with 
concurrent controls[27], we piloted the Outreach service to AKI patients. Intervention and control 
patient recruitment was based on defined geographical (postcode) areas. The 2011 UK census 
gave the usual resident population in the intervention and control areas as 306,309 and 364,234, 
respectively. The study was approved by the National Research Ethics Service (Reference: 
14/EM/0184), and registered at ClinicalTrials.gov (NCT02398682). It was funded by the Research 
for Patient Benefit programme of the UK National Institute for Healthcare Research (PB-PG-1111-
26038). The study was focused on providing AKI Outreach to clinicians. We wrote to all enrolled 
patients giving them an “opportunity to dissent,” or “opt out” of the study.  
Patients with an electronic AKI alert[11, 28] were screened, and inclusion and exclusion criteria 
were applied (figure 1, see [25]). The inclusion criteria were: an adult (≥18 years) patient with an 
Alert (stages 1 to 3), due to AKI detected from a serum creatinine from Heartlands or Good Hope 
Hospitals, or their associated postcodes for community patients. Major exclusion criteria included 
these: deceased at the time of Outreach team intervention; already referred to Nephrology or 
accepted for dialysis by the Renal Unit; the terminal phase of malignancy or end stage major organ 
disease; and lacking mental capacity.[25] Recurrent AKI was not part of the analysis, and patients 
could not be enrolled in more than one phase.  
The trial had two phases and four groups (two during each phase, supplementary figure 1). During 
the 2-month Before phase in April to May 2015, patients in the two groups (Heartlands and area, 
and Good Hope and area) were observed for trial outcomes, without any intervention, thus defining 




During the 5-month ‘After’ phase in June to November 2015 the intervention was delivered to the 
intervention group (Heartlands and area) only, and patients treated at Good Hope hospital and 
area continued to receive standard care. At Heartlands the intervention was provided for AKI 
patients in secondary and primary care, described elsewhere.[25] In brief, there was a stage based 
approach to AKI outreach[25], using a working-hours team consisting of a Renal Fellow, a Critical 
Care outreach nurse with AKI experience, and a Consultant Nephrologist. For patients in primary 
care the call went to their General Practitioner.. We assessed “Fidelity” (adherence to 




The purpose of this study was to determine likely outcome rates in and assess the feasibility of a 
full cluster randomised study[25]. The primary outcome was a composite of: 
A. All-cause death within 30 days; 
B. Any need for dialysis (intermittent haemodialysis or continuous renal replacement therapy) 
within 30 days; 
C. Progression of AKI stage after enrolment, and without dialysis within 30 days after the alert 
(stage progression is stage 1 deteriorating to 2 or 3; stage 2 deteriorating to stage 3). 
 
Secondary outcomes 
These events as given in the discharge letter: 
1. Cause of AKI: new glomerulonephritis or new urinary obstruction diagnosis. 
2. Complication of AKI not requiring dialysis: new pulmonary oedema, uraemia ≥30 mmol/L or 








The sample size was calculated with the intent of estimating uncertainty of outcomes, to inform the 
design of the future cluster trial. Our previous work suggested that the combined outcome would 
be seen in about 40% of patients having an alert. With a sample size of >1000 (intervention 
group—Heartlands and area, after phase), a 95% CI of width 6% (37% to 43%) can be calculated. 
A sample size of 370 (control group—Good Hope and area, after phase) will allow us to produce a 
95% CI of width 10% (35% to 45%). To limit multiple significance testing in a pilot study, this was 
not done for outcomes other than those specified above. 
 
Statistical analysis 
Analyses were used to describe the characteristics of participants in each location and phase of 
the study, with appropriate summary measures reported. The primary outcome was estimated for 
each study site and phase of the study and 95% confidence intervals for these estimates were 
provided also. Descriptive statistics were also provided for secondary outcomes by group and 
phase of the study. Exploratory analyses were undertaken, using a logistic regression model (with 
the primary composite outcome and components of this used in separate models) to obtain 
adjusted estimates of differences between study areas and phases (an interaction term was used 






The trial recruitment is shown in two Consort diagrams (Figure 1). Recruitment was based on 
geographical area, and considerable numbers of community patients were excluded simply 
because they were out of area for either hospital. The results of 1762 eligible patients are 
presented here. Our health economic study has been published.[29] 
 
Baseline characteristics 
Most (82.1%) enrolled patients were in hospital at the time of enrolment, 17.6% in a community 
location (including outpatients), and 0.3% in another or unspecified location. Participants for all four 
groups in the study were typical of the spectrum of the AKI patients. However, the control hospital 
serves a more affluent but ageing population, in a less ethnically diverse area of Northeast 
Birmingham. The intervention hospital is in a poorer area of East Birmingham with a somewhat 
younger, more ethnically diverse population. Those in the control hospital were older, with a higher 
proportion of women and patients of European origin (see Table 1).  All groups had a similar 
spread of AKI stages and non-renal, non-malignant comorbidities.  
 
Dynamic patient flows in entire cohort 
At enrolment, current patient residence was: living in own home 1630 (92%); in sheltered home 58 
(3.3%), in residential home 26 (1.5%), and in Nursing home, or other facility (e.g. Prison or Mental 
Health) 48 (2.7%). At the time of the Alert 1445 (82.0%) were on a hospital ward (including the 
emergency department), but altogether 1540 (87.4%) were admitted within 14 days of the alert. Of 
the 1540 admitted patients, 195 (12.7%) died in hospital. Of the 1345 patients discharged alive, 92 
(6.8%) were discharged to a higher level of care than they required at admission, 2 (0.1%) were 
discharged to a lower level of care, and the remainder showed no change in care at discharge, 
based on residence alone. The median (IQR) length of stay from enrolment to discharge (which 
was not total length of stay) was 6.5 (2.5 – 13.7) days. Two-hundred-and-thirty (14.9%) of the 1540 
admitted patients were enrolled on the day of discharge or after discharge, showing the rapid 
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movement of patients out of the hospital system. 59 of the 744 (7.9%) in the intervention phase at 
the intervention hospital were enrolled on the day of discharge or after discharge. 
 
Causes and course of acute kidney injury 
The four groups showed a similar range of causes of AKI, notably for the top trio of hypovolaemia, 
sepsis and drug toxicity (table 2). Only the intervention hospital has inpatient urology care, and it 
had a higher proportion of patients with obstructive or post-renal causes for AKI, likely for that 
reason.  
 
Interventions in the After phase at the Intervention Hospital (table 3) 
326 of 744 (43.8%) patients had their laboratory AKI alert issued in working hours, when the team 
was available, whereas 56.2% of alerts were issued out of hours. The interventions were delivered 
at a median of 15.7 hours (interquartile range 3.9 to 37.2) after the time of the AKI alert. In the 
active intervention phase at the Intervention Hospital, a median of 3 (interquartile range 2-3) 
interventions were recommended per patient. These were a range of recommended interventions 
across best practice nephrological care for the patients. Recommendations to record weights 
appeared under-utilised, compared to urine output monitoring. Amongst medication changes, 551 
of 830 (63%) stoppages of drugs had been made by the primary clinical team due to AKI. 329 
(37%) further changes were recommended by Outreach team (0.5 per patient), mainly “Stop” 
recommendations. 
 
Primary and secondary outcomes 
Relatively low rates of the primary outcomes of death within 30 days (11-15%), or requirement for 
any renal replacement therapy (RRT, 0 – 3.1%) were seen across all four groups (table 4). AKI 
stage progression occurred at a rate of 4-8%. The challenges of timely intervention were shown by 
the finding that overall 4% of all enrolled patients had stage progression before enrolment, and 7% 
had progression after enrolment. Similarly, 5 patients required CRRT in ITU/ICU before enrolment, 
and overall 30 patients required RRT after enrolment. The combined primary outcome of death, 
dialysis or stage deterioration showed no difference between groups, with rates of 16-19%.  
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In an exploratory analysis, after Multivariate adjustment to outcomes amongst the four groups, 
adjusting for age, sex, ethnicity, location of residence, hospital ward location, and total non-Renal 
non-malignant comorbidities, the interaction of the Intervention hospital during the After phase 
showed a lower odds ratio for the combined primary outcome, OR 0.73 (95% CI 0.42, 1.26, p = 
0.26). Low rates of secondary outcomes, based on discharge diagnoses, were seen (new 
glomerulonephritis, urinary tract obstruction, pulmonary oedema, hyperkalaemia (≥ 6.0 mmol/L) or 
uraemia, table 4). 
 
Fidelity 
A non-random sample of twenty patients was separately consented for this sub-study at the 
Intervention hospital in the After phase. For these patients a median of four (interquartile range 2 – 
5) recommendations (non-drug and drug) were made, for which an extensive paper notes review 
showed that 64 of 78 (82%) were adhered to. Failure to carry out urine dipstick testing accounted 
for 5 of 14 (36%) recommendations that were not implemented. 
 
Stage 3 patients in the Intervention phase 
Our protocol called for stage-based care, as recommended by KDIGO. For patients with a stage 3 
alert in the Intervention Hospital during the Intervention phase, this included a ward visit by a 
Nephrologist, and a clinic visit to a Nephrologist after discharge for survivors. Overall there were 
107 patients who reached stage 3: 66 with a stage 3 alert at enrolment; 38 who later had a stage 3 
alert after enrolment; 2 who were stage 3 only by virtue of needing RRT, and 1 who became stage 
3 after the intervention phase had ended. Including consults by Nephrology colleagues, we carried 
out a ward visit on 85 of the 104 patients (82%) who had a stage 3 alert during the study.  
28 of the entire group of 107 (26%) died during their hospital stay; 5 were discharged with end of 
life care. So regarding clinic visits for the 104 with a stage 3 alert during the study (figure S3), 33 
had died or were end of life; 44 were seen by the AKORDD team; 14 were seen by Nephrology or 
a specialist directly managing the cause of AKI; 5 did not attend their appointment; and we were 
unable to contact/agree an appointment for 8 patients. Including appointments by Nephrology or 





Referral of patients with AKI is a complex process, typically relying on the hospital or primary care 
team to refer to their local nephrology service. The AKORDD study was a large pilot for a Cluster 
randomised study, aiming to provide Outreach to the primary clinical teams managing eligible 
patients with AKI, either in primary or in secondary care. Our study was 4 × [23] to 10 × [24] the 
size of previous studies, and the first with concurrent controls. Using an “opt out” form of consent, 
patients were chiefly excluded for predictable reasons: they had already been seen or referred to 
Nephrology; early death of very sick patients before the intervention could be delivered, or patients 
lacking capacity (including those with advanced dementia) to understand the opt out consent. With 
large numbers of patients anticipated and recruited across a large geographical area, the 
intervention was chiefly delivered by phone to a member of the clinical team responsible for 
continuing care of the patient, in addition stage 3 AKI patients were visited by a Nephrologist. 
There have not been any trials of Nephrology follow-up for stage 3 survivors, but rather 
observational studies suggesting benefit,[30] and ours is the first study to systematically attempt 
this. Amongst the interventions advised, many were relatively simple interventions for the care of 
the AKI patient, consistent with the known limitations of acute care for AKI patients[8] and previous 
experience.[23, 24] The interventions were largely delivered in a timely fashion, at a median of 
about 16 hours after the Alert, comparable to 13[24] - 14[23] hours in previous much smaller 
studies. The patients were predominantly elderly and multimorbid, requiring a wide range of 
different interventions. A moderate number of interventions were advised, and interventions need 
to be further developed to address common comorbidities co-existing with AKI, condition by 
condition. It is known in stroke care that the delivery of a higher number of interventions is 
associated with better outcomes.[31] We also carried out qualitative work which highlighted the 
widely disparate assistance desired by the targeted primary teams, ranging from critical care 
through to primary care (not shown). Stage based care for AKI across a health economy is 
challenging, with frequent patient movement between the community and hospital care or vice 
versa, and with the frail elderly survivors of AKI. Ward and clinic visits were a logistical challenge, 
particularly for those patients who had a Stage 3 alert at any time after enrolment (figure S3). We 
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achieved, with Nephrology colleagues, ward visits to 82% of stage 3 patients during the 
intervention phase. Outpatient follow-up of sick survivors was also challenging (albeit successful), 
even with the use of a virtual clinic and telephone discussions with patients. We achieved, together 
with Nephrology and other relevant specialist colleagues, clinic follow-up of 82% of survivors.  
The outcomes of death or need for dialysis showed a lower than expected frequency, possibly 
partly due to the exclusion of some of the sickest patients (above). The usage of dialysis was low, 
consistent with the 3 to 4% usage seen in our studies in 2008[19] and 2009,[23] although higher 
than the 1% incidence in one other study, carried out in the US in 2008-9.[24]  
 
Strengths and limitations 
Our study has several strengths. The setup of the Outreach team was realistic, given the large 
numbers of patients and working hours nature of the team. Providing a dedicated, seven day a 
week team, separate from the Nephology team, including out-of-hours, was not feasible. 
Nevertheless, the Outreach provided dealt with a group of patients very similar to those seen by 
consulting Nephrologists, albeit on a much larger scale. This was the first large scale study to use 
Outreach across a well-defined healthcare economy, including both primary and secondary care. 
This required the introduction of AKI alerts[28] in both of these sectors in the NHS locally. The 
linking of an AKI alert trigger to outreach response has demonstrated that specialist nephrology 
recommendations can be conveyed to a wide range of healthcare staff managing AKI, in a timely 
and effective way. The stage-based approach with more intensive intervention for stages 2 and 3 
and the AKI follow up clinic were very largely successful.  
The limitations of the trial were mainly inherent in the design of the pragmatic study. Stage 1 AKI 
patients had a “one-time” outreach intervention, necessitated by their very considerable numbers. 
However, stages 2 and 3, including those with stage progression, did receive more intensive 
intervention[25]. Within the control group it was not feasible to measure time to Nephrology referral 
to a number of Nephrologists, working outside the trial. We did not determine possible 
recommendations for control patients during the trial, as the call needed to determine these would 
have been an intervention. As a pilot study it lacked randomised clusters, so the patients in the 
control and intervention area were subtly different. A disadvantage of the pragmatic nature of the 
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intervention, with a modest team working “in hours”, is that the intervention was inevitably 
sometimes delivered after the AKI was recovering or resolved. In conclusion, we found that AKI 
outreach can be delivered to large numbers of patients across a healthcare economy or area, in a 
reasonably timely fashion using a working hours team.  
Trial evidence to support a clear set of single interventions that can be usefully combined to 
improve AKI outcomes is lacking. A large prospective National audit of stage 3 acute kidney injury 
in England in 2012 looked at care processes associated on multivariate analysis with outcome.[32] 
It found that dipstick urinalysis, medication review, discussion with a nephrologist and acceptance 
for transfer to a renal unit were associated with higher survival, but not early review by a senior 
doctor, acceptance for transfer to critical care or requirement for renal replacement therapy.  Our 
trial focused on delivery of the care processes known to be associated with improved outcome.  
Our trial was not powered to show a difference in outcome rates, highlighting the larger number of 
clusters and patients needed to demonstrate whether Outreach can affect outcomes. Such a 
cluster randomised trial might include a six or seven-day service, to reduce the time to intervention 
further and mitigate at least some of the “weekend effect,”[33] although the exact nature of this 
effect remains unclear.[34] Future studies could concentrate on mid-range to higher risk patients, 
for example those that are stage 2 or 3 AKI. 
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TABLE 1:  BASELINE CHARACTERISTICS OF THE FOUR GROUPS IN THE AKORDD STUDY.  
1 Kruskal Wallis test; 2 Chi square test; 3 Independent home living or sheltered accommodation or equivalent 4 Including Emergency 















‘AFTER’ PHASE  
INTERVENTION 
HOSPITAL: ‘AFTER’  
 
p 
 N=239 N=382 N=397 N=744  
Age (years); mean (SD) 
 
72.7 (16.4) 69.4 (17.9) 72.6 (15.3) 69.4  (16.6) 0.002 1 
Sex (male); n (%) 
 
108 (45) 218 (57) 182 (46) 435 (58) <0.001 2 
Ethnicity (European); n (%) 226 (95) 271 (71) 361 (91) 578 (78) <0.001 2 
Residence (at home3); n(%) 222 (93) 368 (96) 384 (97) 717 (96) 0.27 2 




1.24 (1.09) 1.20 (1.10) 1.08 (1.07) 1.24 (1.13) 0.13 1 
AKI stage 1; n (%) 
 
179 (75) 275 (72) 290 (73) 553 (74) 
0.85 2 
AKI stage 2; n (%) 
 
33 (14) 63 (16) 68 (17) 125 (17) 
AKI stage 3; n(%) 
 
27 (11) 44 (12) 39 (10) 66 (9) 
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All major contributory factors were listed for each patient. Patients may have more than one cause of AKI, as determined from discussion with 
primary team and the electronic patient record. Figures are number (percentage) of patients or mean (SD) [number of survivors].  
1 Determined by Outreach team after discussion with primary team.  2 Last observation carried forward.   
GROUP CONTROL 
HOSPITAL: 
BEFORE STUDY  




n = 382 
CONTROL 
HOSPITAL: 
AFTER STUDY  




n = 744 
Major causes of AKI1 
Hypovolaemia 137 (57.3) 235 (61.5) 248 (62.5) 471 (63.3) 
Sepsis 81 (33.9) 123 (32.2) 145 (36.5) 283 (38.0) 
Drug toxicity 114 (47.7) 179 (46.9) 218 (54.9) 386 (51.9) 
Post renal 18 (7.5) 45 (11.8) 23 (5.8 ) 83 (11.2) 
Surgical 20 (8.4) 45 (11.8) 38 (9.6) 84 (11.3) 
Creatinine (Cr) µmol/L 
Baseline Cr 95 (44)       [239] 102 (74)     [382] 93 (47)      [397] 92 (37)       [744] 
Alert Cr 194 (197)   [239] 190 (126)   [382] 177 (107)  [397] 174 (102)   [744] 
Peak Cr 209 (203)   [239] 217 (160)   [382] 192 (122)  [397] 194 (121)   [744] 
30-day Cr 2 109 (71)     [205] 118 (88)     [338] 120 (77)    [337] 108 (59)     [654] 
90-day Cr 2 105 (54)     [184] 118 (109)   [313] 113 (72)    [307] 102 (46)     [616] 
182-day Cr 2 106 (60)     [172] 118 (105)   [291] 113 (85)    [292] 102 (46)     [566] 
365-day Cr 2 107 (62)     [161] 122 (125)   [253] 120 (105)  [270] 105 (49)     [524] 
CKD EPI eGFR mL/min/1.73m2 
Baseline eGFR 67 (24)       [239] 71 (28)       [382] 70 (26)      [397] 73 (26)       [744] 
Alert eGFR 35 (17)       [239] 37 (19)       [382] 36 (18)      [397] 39 (19)       [744] 
Nadir eGFR 32 (17)       [239] 34 (21)       [382] 34 (18)      [397] 36 (19)       [744] 
30-day eGFR 2 62 (26)       [205] 64 (30)       [338] 58 (27)      [337] 65 (28)       [654] 
90-day  eGFR 2 63 (26)       [184] 66 (29)       [313] 60 (26)      [307] 67 (26)       [616] 
182-day eGFR 2 63 (26)       [172] 67 (30)       [291] 62 (26)      [292] 68 (26)       [566] 
365-day  eGFR2 63 (26)       [161] 67 (30)       [253] 62 (27)      [270] 66 (27)       [524] 
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There were a median (IQR) of 3.0 (2.0 – 3.0) non-drug recommendations per patient in the 
Intervention group. * “Stop” recommendations: Renin-angiotensin system agent 115 (35%), 
diuretic 59 (18%), other antihypertensives 50 (15%), non-steroidal anti-inflammatory agent 




n = 744 
Bedside monitoring, oxygen and fluids 
Urinalysis 609 
Formal urine output monitoring 104 
Standing heart rate and BP 29  
Daily weights 8 
High flow oxygen 2 
Start or increase intravenous fluids 156 
Start or increase oral fluids 72 
Decrease or stop intravenous fluids 7 
Other fluid recommendation 23 
Drug recommendations 
Stop 329* 
Start or restart 24 
Avoid planned drug (e.g. contrast) 15 
Previously stopped by primary team 551 
Pathology tests 
Repeat Urea, creatinine, electrolytes 
or advice about frequency of testing 
684 
Venous bicarbonate 36 
Venous lactate 19 
Arterial blood gases 2 
Full blood count 5 
Clotting 2 
Blood cultures 3 
Urine microscopy and culture 16 
Imaging 
Avoid contrast (if being considered) 17 
Urinary tract ultrasound 18 
Other imaging recommendation 8 
Patient pathway 
Urgent Renal outpatient appointment 12 
Admit to hospital 4 
Senior medical review 12 
Transfer to Renal Inpatient care 6 
Refer to Critical Care for transfer 1 
Allied Health Professional referral and discharge 
Nutrition review – refer to dietician 26 
Physiotherapy 7 














 ‘BEFORE’ PHASE ‘AFTER’ PHASE  
 CONTROL  INTERVENTION  CONTROL  INTERVENTION  p 
Primary outcomes n = 239 n = 382 n = 397 n = 744   
30-day mortality n/N 34/239 44/382 60/397 90/744   
% (95% CI) 14.2 (10.1, 19.3) 11.5 (8.5, 15.2) 15.1 (11.7, 19.0) 12.1 (9.8, 14.7) 0.371 
Stage progression 10/239  31/382 (8.1) 23/397 64/744   
 % (95% CI) 4.2 (2.0, 7.6) 8.1 (5.6, 11.3) 5.8 (3.7, 8.6) 8.6 (6.7, 10.9) 0.0711 
Any RRT (CRRT or HD) 0/239 12/382 5/397 13/744   
 % (95% CI) 0.0 (0.0, 1.5)* 3.2 (1.6, 5.4) 1.3 (0.4, 2.9) 0.4 (0.9, 0.3) 0.071 
Combined primary outcome 39/239 72/382 73/397 141/744   
% (95% CI) 16.3 (11.9, 21.6) 18.8 (15.0, 23.1) 18.4 (14.7, 22.6) 19.0 (16.2, 22.0) 0.831 
Secondary outcomes 
New glomerulonephritis diagnosis 1/239 7/382 7/397 12/744   
 % (95% CI) 0.4 (0.0, 2.3) 1.8 (0.7, 3.7) 1.8 (0.7, 3.6) 1.6 (0.8, 2.8) 0.552 
New Urinary tract obstruction diagnosis 9/239 28/382 3/397 19/744    
 % (95% CI) 3.8 (1.7, 7.0) 7.3 (4.9, 10.4) 0.8 (0.2, 2.2) 2.6 (1.5, 4.0) 0.012 
New Pulmonary oedema complication 9/239 (3.8) 24/382 (6.3) 1/397 (0.3) 14/744 (1.9)   
 % (95% CI) 3.8 (1.7, 7.0) 6.3 (4.1, 9.2) 0.3 (0.0, 1.4) 1.9 (1.0, 3.1) 0.032 
New hyperkalaemia  
(≥ 6.0 mmol/L) 
0/239 16/382 (4.2) 8/397 (2.0) 4/744 (0.5)   
 % (95% CI) 0.0 (0.0, 1.5)* 4.2 (2.4, 6.7)  2.0 (0.8, 3.9) 0.5 (0.1, 1.4) 0.552 
New Uraemia 3/239 (1.3) 19/382 (5.0) 0/397 9/744 (1.2)   





Figure 1. Consort diagrams for the Before and After phases. 






FIGURE S1: Trial Design – reproduced with permission. 
FIGURE S2. Stage 3 AKI patients during intervention phase at intervention hospital.  
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